How to buy Kadmon stock (KDMN)

Kadmon is a biotechnology business based in the US. Kadmon shares (KDMN) are listed on the NASDAQ and all prices are listed in US Dollars. Kadmon employs 127 staff and has a trailing 12-month revenue of around $19.7 million.

Our top picks for where to buy Kadmon stock

Buy Kadmon stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Kadmon stock price (NASDAQ: KDMN)

Use our graph to track the performance of KDMN stocks over time.

Kadmon shares at a glance

• Key figures

Information last updated 2022-01-02.

52-week range	$0.00 - $0.00
50-day moving average more info button	$8.66
200-day moving average more info button	$5.35
Wall St. target price	$12.10
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.71

Is it a good time to buy Kadmon stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kadmon price performance over time

Historical closes compared with the close of $N/A from 2021-12-08

1 week (2024-10-16)	N/A
1 month (2024-09-23)	N/A
3 months (2024-07-23)	N/A
6 months (2024-04-23)	N/A

1 year (2023-10-23)	N/A
2 years (2022-10-23)	N/A
3 years (2021-10-27)	9.42
5 years (2019-10-25)	3.15

Kadmon financials

Revenue TTM	$19.7 million
Gross profit TTM	$6.3 million
Return on assets TTM	-29.66%
Return on equity TTM	-153.99%
Profit margin	0%
Book value	$0.08
Market Capitalization more info button	$1.7 billion

TTM: trailing 12 months

Kadmon share dividends

We're not expecting Kadmon to pay a dividend over the next 12 months.

Kadmon share price volatility

Over the last 12 months, Kadmon's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kadmon's is 1.1231. This would suggest that Kadmon's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Kadmon overview

Kadmon Holdings, Inc. , a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp.

Frequently asked questions

What percentage of Kadmon is owned by insiders or institutions?
Currently 0.161% of Kadmon shares are held by insiders and 103.709% by institutions. How many people work for Kadmon?
Latest data suggests 127 work at Kadmon. When does the fiscal year end for Kadmon?
Kadmon's fiscal year ends in December. Where is Kadmon based?
Kadmon's address is: 450 East 29th Street, New York, NY, United States, 10016 What is Kadmon's ISIN number?
Kadmon's international securities identification number is: US48283N1063 What is Kadmon's CUSIP number?
Kadmon's Committee on Uniform Securities Identification Procedures number is: 48283N106